PKG-I inhibition attenuates vascular endothelial growth factor-stimulated angiogenesis

Vascular Pharmacology

Volumn 53, Issue 5-6, 2010, Pages 215-222

  Koika, Vasiliki ^a   Zhou, Zongmin ^b   Vasileiadis, Ioannis ^b   Roussos, Charis ^b   Finetti, Federica ^c   Monti, Martina ^c   Morbidelli, Lucia ^c   Papapetropoulos, Andreas ^a  

^a UNIVERSITY OF PATRAS   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c UNIVERSITY OF SIENA   (Italy)

Author keywords

Angiogenesis; CGMP; PKG; Vascular endothelium; VEGF

Indexed keywords

ARGINYLGLUTAMINYLISOLEUCYLLYSYLISOLEUCYLTRYPTOPHYLPHENYLALANYLGLUTAMINYLASPARAGINYLARGINYLARGINYLMETHIONYLLYSYLTRYPTOPHYLLYSYLLYSINE; ARGINYLGLUTAMINYLISOLEUCYLLYSYLISOLEUCYLTRYPTOPHYLPHENYLALANYLGLUTAMINYLASPARAGINYLARGINYLARGINYLMETHIONYLLYSYLTRYPTOPHYLLYSYLLYSYLLEUCYLARGINYLLYSYLLYSYLLYSYLLYSYLLYSYLHISTIDINE; CYCLIC GMP; CYCLIC GMP DEPENDENT PROTEIN KINASE; CYCLIC GMP DEPENDENT PROTEIN KINASE INHIBITOR; LEUCYLARGINYLLYSYLLYSYLLYSYLLYSYLLYSYLHISTIDINE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; TYROSYLGLYCYLARGINYLLYSYLLYSYLARGINYLARGINYLGLUTAMINYLARGINYLARGINYLARGININE; TYROSYLGLYCYLARGINYLLYSYLLYSYLARGINYLARGINYLGLUTAMINYLARGINYLARGINYLARGINYLPROLYLPROLYLLEUCYLARGINYLLYSYLLYSYLLYSYLLYSYLLYSYLHISTIDINE; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; VASODILATOR STIMULATED PHOSPHOPROTEIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL GROWTH; CELL MIGRATION; CHICKEN; CHORIOALLANTOIS; CONTROLLED STUDY; CORNEA; CORNEA NEOVASCULARIZATION; ENDOTHELIUM CELL; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RABBIT; RAT;

ANIMALS; CELLS, CULTURED; CHICK EMBRYO; CHORIOALLANTOIC MEMBRANE; CORNEA; CYCLIC GMP-DEPENDENT PROTEIN KINASES; ENDOTHELIAL CELLS; FLUORESCEINS; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASES; NEOVASCULARIZATION, PHYSIOLOGIC; NITRIC OXIDE; PEPTIDE FRAGMENTS; PEPTIDES; PHOSPHORYLATION; RABBITS; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 78449231585     PISSN: 15371891     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vph.2010.08.004     Document Type: Article

References (42)

1. Aicher A., Heeschen C., Feil S., Hofmann F., Mendelsohn M., Feil R., Dimmeler S. cGMP-dependent protein kinase I is crucial for angiogenesis and postnatal vasculogenesis. PLoS ONE 2009, 4:e4879.
2. Butt E. cGMP-dependent protein kinase modulators. Handb. Exp. Pharmacol. 2009, 191:409-421.
3. Butt E., Abel K., Krieger M., Palm D., Hoppe V., Hoppe J., Walter U. cAMP- and cGMP-dependent protein kinase phosphorylation sites of the focal adhesion vasodilator-stimulated phosphoprotein (VASP) in vitro and in intact human platelets. J. Biol. Chem. 1994, 269:14509-14517.
4. Buttke T., McCubrey J., Owen T. Use of an aqueous soluble tetrazolium/formazan assay to measure viability and proliferation of lymphokine-dependent cell lines. J. Immunol. Methods 1993, 157:233-240.
5. Carmeliet P. Angiogenesis in health and disease. Nat. Med. 2003, 9:653-660.
6. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005, 438:932-936.
7. Dostmann W.R.G., Taylor M.S., Nickl C.K., Brayden J.E., Frank R., Tegge W.J. Highly specific, membrane-permeant peptide blockers of cGMP-dependent protein kinase Ialpha inhibit NO-induced cerebral dilation. Proc. Natl Acad. Sci. USA 2000, 97:14772-14777.
8. Draijer R., Vaandrager A.B., Nolte C., de Jonge H.R., Walter U., van Hinsbergh V.W.M. Expression of cGMP-dependent protein kinase I and phosphorylation of its substrate, vasodilator-stimulated phosphoprotein, in human endothelial cells of different origin. Circ. Res. 1995, 77:897-905.
9. Feil R., Lohmann S., de Jonge H., Walter U., Hofmann F. Cyclic GMP-dependent protein kinases and the cardiovascular system: insights from genetically modified mice. Circ. Res. 2003, 93:907-916.
10. Ferrara N., Kerbel R. Angiogenesis as a therapeutic target. Nature 2005, 438:967-974.
11. Ferrara N., Gerber H.-P., LeCouter J. The biology of VEGF and its receptors. Nat. Med. 2003, 9:669-676.
12. Folkman J., Shing Y. Angiogenesis. J. Biol. Chem. 1992, 267:10931-10934.
13. Fukumura D., Gohongi T., Kadambi A., Izumi Y., Ang J., Yun C.-O., Buerk D.G., Huang P.L., Jain R.K. Predominant role of endothelial nitric oxide synthase in vascular endothelial growth factor-induced angiogenesis and vascular permeability. Proc. Natl Acad. Sci. USA 2001, 98:2604-2609.
14. Gratton J., Lin M., Yu J., Weiss E., Jiang Z., Fairchild T., Iwakiri Y., Groszmann R., Claffey K., Cheng Y., Sessa W. Selective inhibition of tumor microvascular permeability by cavtratin blocks tumor progression in mice. Cancer Cell 2003, 4:31-39.
15. Halbrügge M., Friedrich C., Eigenthaler M., Schanzenbacher P., Walter U. Stoichiometric and reversible phosphorylation of a 46-kDa protein in human platelets in response to cGMP- and cAMP-elevating vasodilators. J. Biol. Chem. 1990, 265:3088-3093.
16. Hofmann F. The biology of cyclic GMP-dependent protein kinases. J. Biol. Chem. 2005, 280:1-4.
17. Hood J., Granger H.J. Protein kinase G mediates vascular endothelial growth factor-induced Raf-1 activation and proliferation in human endothelial cells. J. Biol. Chem. 1998, 273:23504-23508.
18. Kroll J., Waltenberger J. A novel function of VEGF receptor-2 (KDR): rapid release of nitric oxide in response to VEGF-A stimulation in endothelial cells. Biochem. Biophys. Res. Commun. 1999, 265:636-639.
19. Lucas K.A., Pitari G.M., Kazerounian S., RuizStewart I., Park J., Schulz S., Chepenik K.P., Waldman S.A. Guanylyl cyclases and signaling by cyclic GMP. Pharmacol. Rev. 2000, 52:375-414.
20. McMullen M., Keller R., Sussman M., Pumiglia K. Vascular endothelial growth factor-mediated activation of p38 is dependent upon Src and RAFTK/Pyk2. Oncogene 2004, 23:1275-1282.
21. Morbidelli L., Pyriochou A., Filippi S., Vasileiadis I., Roussos C., Zhou Z., Loutrari H., Waltenberger J., Stössel A., Giannis A., Ziche M., Papapetropoulos A. The soluble guanylyl cyclase inhibitor NS-2028 reduces vascular endothelial growth factor-induced angiogenesis and permeability. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2010, 298:R824-R832.
22. Murohara T., Asahara T., Silver M., Bauters C., Masuda H., Kalka C., Kearney M., Chen D., Symes J.F., Fishman M.C., Huang P.L., Isner J.M. Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. J. Clin. Invest. 1998, 101:2567-2578.
23. Murohara T., Horowitz J., Silver M., Tsurumi Y., Chen D., Sullivan A., Isner J. Vascular endothelial growth factor/vascular permeability factor enhances vascular permeability via nitric oxide and prostacyclin. Circulation 1998, 97:99-107.
24. Nagy J., Benjamin L., Zeng H., Dvorak A., Dvorak H. Vascular permeability, vascular hyperpermeability and angiogenesis. Angiogenesis 2008, 11:109-119.
25. Oliveira C.J.R., Schindler F., Ventura A.M., Morais M.S., Arai R.J., Debbas V., Stern A., Monteiro H.P. Nitric oxide and cGMP activate the Ras-MAP kinase pathway-stimulating protein tyrosine phosphorylation in rabbit aortic endothelial cells. Free Radic. Biol. Med. 2003, 35:381-396.
26. Papapetropoulos A., Garcia-Cardena G., Madri J.A., Sessa W.C. Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. J. Clin. Invest. 1997, 100:3131-3139.
27. Parenti A., Morbidelli L., Cui X.L., Douglas J.G., Hood J.D., Granger H.J., Ledda F., Ziche M. Nitric oxide is an upstream signal of vascular endothelial growth factor-induced extracellular signal-regulated kinase1/2 activation in postcapillary endothelium. J. Biol. Chem. 1998, 273:4220-4226.
28. Pfeifer A., Ruth P., Dostmann W., Sausbier M., Klatt P., Hofmann F. Structure and function of cGMP-dependent protein kinases. Rev. Physiol. Biochem. Pharmacol. 1999, 135:105-149.
29. Pyriochou A., Beis D., Koika V., Potytarchou C., Papadimitriou E., Zhou Z., Papapetropoulos A. Soluble guanylyl cyclase activation promotes angiogenesis. J. Pharmacol. Exp. Ther. 2006, 319:663-671.
30. Pyriochou A., Vassilakopoulos T., Zhou Z., Papapetropoulos A. cGMP-dependent and -independent angiogenesis-related properties of nitric oxide. Life Sci. 2007, 81:1549-1554.
31. Pyriochou A., Zhou Z., Koika V., Petrou C., Cordopatis P., Sessa W., Papapetropoulos A. The phosphodiesterase 5 inhibitor sildenafil stimulates angiogenesis through a protein kinase G/MAPK pathway. J. Cell. Physiol. 2007, 211:197-204.
32. Senthilkumar A., Smith R.D., K.J., Arora N., V.S., Langston W., Chidlow J.H., Barlow S.C., Teng X., Patel R.P., Lefer D.J., C.G.K. Sildenafil promotes ischemia-induced angiogenesis through a PKG-dependent pathway. Arterioscler. Thromb. Vasc. Biol. 2007, 27:1947-1954.
33. Shojaei F., Ferrara N. Antiangiogenesis to treat cancer and intraocular neovascular disorders. Lab. Invest. 2007, 87:227-320.
34. Taylor M., Okwuchukwuasanya C., Nickl C., Tegge W., Brayden J., Dostmann W. Inhibition of cGMP-dependent protein kinase by the cell-permeable peptide DT-2 reveals a novel mechanism of vasoregulation. Mol. Pharmacol. 2004, 65:1111-1119.
35. Yamahara K., Itoh H., Chun T., Ogawa Y., Yamashita J., Sawada N., Fukunaga Y., Sone M., Yurugi-Kobayashi T., Miyashita K., Tsujimoto H., Kook H., Feil R., Garbers D., Hofmann F., Nakao K. Significance and therapeutic potential of the natriuretic peptides/cGMP/cGMP-dependent protein kinase pathway in vascular regeneration. Proc. Natl Acad. Sci. USA 2003, 100:3404-3409.
36. Yu J., deMuinck E., Zhuang Z., Drinane M., Kauser K., Rubanyi G., Qian H., Murata T., Escalante B., Sessa W. Endothelial nitric oxide synthase is critical for ischemic remodeling, mural cell recruitment, and blood flow reserve. Proc. Natl Acad. Sci. USA 2005, 102:10999-11004.
37. Yuan S. Protein kinase signaling in the modulation of microvascular permeability. Vasc. Pharmacol. 2002, 39:213-223.
38. Zachary I. VEGF signalling: integration and multi-tasking in endothelial cell biology. Biochem. Soc. Trans. 2003, 31:1171-1177.
39. Zachary I., Gliki G. Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family. Cardiovasc. Res. 2001, 49:568-581.
40. Ziche M., Morbidelli L. Nitric oxide and angiogenesis. J. Neurooncol. 2000, 50:139-148.
41. Ziche M., Morbidelli L., Masini E., Amerini S., Granger H.J., Maggi C.A., Geppetti P., Ledda F. Nitric oxide mediates angiogenesis in vivo and endothelial cell growth and migration in vitro promoted by substance P. J. Clin. Invest. 1994, 94:2036-2044.
42. Ziche M., Morbidelli L., Choudhuri R., Zhang H.T., Donnini S., Granger H.J., Bicknell R. Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis. J. Clin. Invest. 1997, 99:2625-2634.